Table 5 Summary of myelodysplastic syndrome cell lines: origins, lineage, and key features.
Cell line | Original disease | Lineage | Characteristics | References |
|---|---|---|---|---|
M-TAT | RAEB-MDS | Erythroid or megakaryocytic | Isolated from peripheral blood of 3-years-old patient. | [155] |
Cytokine-dependent (EPO, GM-CSF, SCF, IL3). | ||||
Differentiates in response to EPO but shows reduced hemoglobin when GM-CSF is added. | ||||
MDS92 | RARS-MDS | Myeloid with megakaryocytic differentiation | Isolated from a bone marrow of 52-year-old male. | |
Presence of typical MDS aberrations such as 5q and 17p deletion, monosomy 7 and NRAS mutation. | ||||
Sensitive to cytokines such as GM-CSF and IL-3. | ||||
TER-3 | RAEB-MDS | Erythroid or megakaryocytic | Cytokine-dependent: G-CSF, GM-CSF, IL3, TPO, M-CSF, SCF. | |
TER-3 has surface markers that are strongly positive for myeloid, lymphoid, and megakaryocytic antigens, including CD15, CD19, and CD6. | ||||
Presence of typical MDS aberrations such as monosomy 7,20 and Y. | ||||
MDS-L | MDS (often progressing to AML) | Myeloid | Blastic subline derived from MDS92. | |
A standard preclinical model for developing MDS therapies. | ||||
Sensitive to IL-3 cytokine. | ||||
H3-K27M mutation was detected in MDS-L. | ||||
MDS-L-2007 | MDS with leukemic transformation | Myeloid | MDS-L in the presence of IL-3 generated MDS-L-2007 (H3-K27M–mutant). | [158] |
MDS-LGF | MDS with leukemic features | Myeloid | MDS-L in the absence of IL-3 generated MDS-LGF (H3-K27M–wild type). | [158] |
